Association of HLA B‐ and T‐cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation

Abstract

AbstractBackgroundOptimizing graft survival and diminishing human leukocyte antigen (HLA) sensitization are essential for pediatric kidney transplant recipients. More precise HLA matching predicting epitope mismatches could reduce alloreactivity. We investigated the association of predicted HLA B‐ and T‐cell molecular mismatches with the formation of de novo donor‐specific antibodies, HLA antibodies, rejection, and graft survival.MethodsForty‐nine pediatric kidney transplant recipients transplanted from 2009 to 2020 were retrospectively studied. Donors and recipients were high‐resolution HLA typed, and recipients were screened for HLA antibodies posttransplant. HLA‐EMMA (HLA Epitope MisMatch Algorithm) and PIRCHE‐II (Predicted Indirectly ReCognizable HLA Epitopes) predicted the molecular mismatches. The association of molecular mismatches and the end‐points was explored with logistic regression.ResultsFive recipients (11%) developed de novo donor‐specific antibodies. All five had de novo donor‐specific antibodies against HLA class II, with four having HLA‐DQ antibodies. We found no associations between PIRCHE‐II or HLA‐EMMA with de novo donor‐specific antibodies, HLA sensitization, graft loss, or rejection. However, we did see a tendency towards an increased odds ratio in PIRCHE‐II predicting de novo donor‐specific antibodies formation, with an odds ratio of 1.12 (95% CI: 0.99; 1.28) on HLA class II.ConclusionWhile the study revealed no significant associations between the number of molecular mismatches and outcomes, a notable trend was observed – indicating a reduced risk of dnDSA formation with improved molecular match. It is important to acknowledge, however, that the modest population size and limited observed outcomes preclude us from making definitive conclusions.